【摘要】 目的 探讨儿童急性淋巴细胞白血病（ALL）诱导治疗完全缓解后微小残留病（MRD）与预后的关系。方法 回顾性分析内蒙古自治区人民医院小儿血液科2015年06月—2018年12月期间收治的60例ALL患儿，使用流式细胞术检测患儿第33天MRD,追踪至形态学复发或随访截止日期。定义MRD≥10^-4为微小残留病阳性。结果 60例ALL患儿初诊后根据MRD调整至标危、中危、高危者分别为7例（12%）、42例（70%）、11例（18%）,MRD阳性者13例，4例复发；MRD阴性者47例，2例复发。结论 应用流式细胞术监测ALL患儿的第33天MRD水平可作为评价预后的敏感性指标，用于指导临床个体化治疗。更多还原

【Abstract】 Objective To explore the relationship between the minor residual disease（MRD） after complete remission induction therapy and prognosis in children with acute lymphoblastic leukemia（ALL）. Methods A total of 60 children with ALL admitted to the Pediatric Hematology Department of the People′s Hospital of Inner Mongolia Autonomous Region from June 2015 to December 2018 were analyzed retrospectively. MRD was detected by flow cytometry（FCM） and followed up to the end date of morphological recurrence or follow-up. MRD≥10^-4 was defined as positive for minimal residual disease. Results Among the 60 children with ALL after initial diagnosis, 7（12%）, 42（70%） and 11（18%） were adjusted to standard risk, medium risk and high risk according to MRD. Four of the 13 children with MRD positive recurred, while only 2 of 47 cases with MRD negative recurred. Conclusions FCM-MRD level in children with ALL can be used as a sensitivity index to evaluate prognosis, and can also be used to guide clinical individualized treatment.更多还原